CD8A and neoplasm: Furthermore, evidence suggests losartan remodels the tumour immune landscape by promoting CD8+ T and natural killer (NK) cell infiltration, reprogramming tumour‐associated macrophages (TAMs) and suppressing immunosuppressive cytokines.